United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Trust Point Inc.

Trust Point Inc. raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 45.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,697 shares of the biotechnology company’s stock after purchasing an additional 531 shares during the period. Trust Point Inc.’s holdings in United Therapeutics were worth $599,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of UTHR. Wealth Enhancement Advisory Services LLC boosted its position in shares of United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after buying an additional 39 shares during the period. MBM Wealth Consultants LLC grew its stake in shares of United Therapeutics by 1.9% in the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 41 shares in the last quarter. First Citizens Bank & Trust Co. increased its holdings in shares of United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 48 shares during the period. Signaturefd LLC raised its stake in shares of United Therapeutics by 8.8% during the third quarter. Signaturefd LLC now owns 633 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 51 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in United Therapeutics by 4.9% in the fourth quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 51 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on UTHR shares. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. The Goldman Sachs Group increased their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $378.36.

Insider Activity

In related news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total transaction of $3,536,400.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $911,330.28. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 143,838 shares of company stock worth $53,981,956 in the last 90 days. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $353.43 on Wednesday. The stock has a market cap of $15.78 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57. The firm’s 50 day moving average price is $364.28 and its two-hundred day moving average price is $357.68. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.